| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Diallyl disulfide targets multiple cellular pathways involved in oxidative stress, inflammation, and cancer. It induces antioxidant defense mechanisms by activating the Nrf2 pathway, leading to increased expression of antioxidant enzymes. It reduces the inflammatory response by inhibiting NF-κB activation. The compound's anticancer effects are mediated through induction of apoptosis, cell cycle arrest, and inhibition of cancer cell proliferation. Its multi-targeted activity makes it a valuable tool for studying oxidative stress, inflammation, and cancer biology.
|
|---|---|
| ln Vitro |
In vitro, diallyl disulfide exhibits antioxidant, anti-inflammatory, antimicrobial, and anticancer activities. It induces antioxidant defense mechanisms by activating the Nrf2 pathway and reduces inflammatory response by inhibiting NF-κB activation. The compound's antitumor effect can be enhanced by miR-200b and miR-22. Its activity is concentration-dependent, with effective concentrations typically in the micromolar range. Its multi-functional activity makes it a valuable tool for studying natural product pharmacology, oxidative stress, inflammation, and cancer biology.
|
| ln Vivo |
In vivo, diallyl disulfide has been studied in preclinical models of cancer and inflammation. Its antioxidant, anti-inflammatory, and anticancer effects have been demonstrated in animal models. However, detailed in vivo efficacy data and pharmacokinetic profiles are limited in publicly available sources. The compound is primarily used as a research tool for studying natural product pharmacology. Further studies are needed to fully characterize its therapeutic potential, dosing regimens, and safety profile in vivo.
|
| Enzyme Assay |
The in vitro antioxidant activity assay for diallyl disulfide typically uses cell-based or cell-free systems. For cell-free assays, the compound is tested for its ability to scavenge free radicals using DPPH, ABTS, or ORAC assays. For cell-based assays, cells are treated with the compound and exposed to oxidative stress (e.g., H2O2), and ROS levels are measured using fluorescent probes such as DCFH-DA. Nrf2 activation is assessed by measuring nuclear translocation of Nrf2 by immunofluorescence and expression of Nrf2 target genes (HO-1, NQO1) by qRT-PCR. NF-κB inhibition is assessed by measuring phosphorylation of IκBα and NF-κB nuclear translocation by Western blotting. Positive controls and negative controls are included in each assay run.
|
| Cell Assay |
For in vitro cellular assays, cancer cell lines or immune cells are treated with diallyl disulfide at concentrations ranging from 1 to 100 µM for 24-72 hours. Cell viability is assessed using MTT or CellTiter-Glo assays. Oxidative stress markers (ROS, MDA, GSH) are measured using fluorescent probes and biochemical assays. Inflammatory markers (TNF-α, IL-6, IL-1β) are measured by ELISA. Nrf2 activation and NF-κB inhibition are assessed by Western blotting. Apoptosis is quantified by Annexin V/PI staining and caspase activity assays. Cell cycle distribution is analyzed by propidium iodide staining and flow cytometry. All experiments include appropriate controls and are performed in triplicate.
|
| Animal Protocol |
For in vivo efficacy studies, rodent models of cancer or inflammation are used. Diallyl disulfide is administered orally or intraperitoneally at doses ranging from 1 to 100 mg/kg, typically once or twice daily. Tumor growth is monitored, and inflammatory markers are measured in blood and tissues. Antioxidant enzyme activities are measured in tissue homogenates. All animal procedures should be conducted in accordance with institutional guidelines.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Dearly allyl disulfide known human metabolites include (2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-1-oxo-3-[(E)-3-(prop-2-enyldithio)prop-1-enyl]thioprop-2-yl]amino]-5-oxovalerate and DADSO. The pharmacokinetic properties of diallyl disulfide have been partially characterized. The compound has a molecular weight of 146.27 and is a lipophilic organosulfur compound. Following oral or intraperitoneal administration, it shows moderate absorption with a Tmax of 1-3 hours. Plasma half-life is estimated to be 2-4 hours. The compound distributes into tissues including liver, kidney, and lung. Metabolism is primarily hepatic, with oxidation and conjugation as major pathways. The compound is eliminated primarily via biliary and renal excretion. Further PK studies are needed for comprehensive characterization. |
| Toxicity/Toxicokinetics |
Preclinical toxicology studies of diallyl disulfide are limited. In acute toxicity studies in rodents, the compound is tolerated at doses up to 100 mg/kg with no significant adverse effects. In repeat-dose studies, the no-observed-adverse-effect level (NOAEL) has not been definitively established. No significant organ toxicity or hematological abnormalities are reported at pharmacological doses. The compound shows no evidence of genotoxicity in standard in vitro assays. The safety profile supports further preclinical development, though comprehensive toxicology studies are needed to fully assess the compound's safety for potential clinical advancement. The compound is for research use only and is not approved for human use.
|
| References |
|
| Additional Infomation |
Diallyl disulfide is an organic disulfide, wherein the organic group is allyl. It has been isolated from garlic and Allium species. It possesses dual activities against tumors, fungi, and plant metabolism. It has been reported that diallyl disulfide is found in allium ursinum, leek (Allium ampeloprasum), and several other organisms with relevant data.
Diallyl disulfide is a bioactive garlic-derived organosulfur compound with antioxidant, anti-inflammatory, antimicrobial, and anticancer effects. It activates Nrf2 and inhibits NF-κB. The compound is not approved for human use and has not entered clinical trials. It is available as a high-purity research reagent for laboratory use only. Its multi-targeted activity makes it a valuable tool for studying oxidative stress, inflammation, and cancer biology. |
| Molecular Formula |
C6H10S2
|
|---|---|
| Molecular Weight |
146.2736
|
| Exact Mass |
146.022
|
| CAS # |
2179-57-9
|
| PubChem CID |
16590
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
185.0±0.0 °C at 760 mmHg
|
| Flash Point |
42.4±25.8 °C
|
| Vapour Pressure |
1.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.534
|
| LogP |
3.26
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
8
|
| Complexity |
58.9
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C([H])([H])C([H])=C([H])[H])SC([H])([H])C([H])=C([H])[H]
|
| InChi Key |
PFRGXCVKLLPLIP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H10S2/c1-3-5-7-8-6-4-2/h3-4H,1-2,5-6H2
|
| Chemical Name |
3-(prop-2-enyldisulfanyl)prop-1-ene
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~683.67 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (17.09 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (17.09 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (17.09 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.8367 mL | 34.1834 mL | 68.3667 mL | |
| 5 mM | 1.3673 mL | 6.8367 mL | 13.6733 mL | |
| 10 mM | 0.6837 mL | 3.4183 mL | 6.8367 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
